7:06 am Biogen Idec and Sobi announce positive top-line efficacy and safety results from Phase 3 pediatric study of investigational therapy eloctate (rFVIIIFc) for hemophilia A; data showed twice-weekly prophylactic dosing with ELOCTATE mai
View todays social media effects on BIIB
View the latest stocks trending across Twitter. Click to view dashboard
See who Biogen is hiring next, click here to view
